An oncogenic enhancer promotes melanoma progression via regulating ETV4 expression

Area of Science:

• Genomics
• Cancer Biology
• Molecular Oncology

Background:

• Enhancers are critical gene regulatory elements implicated in development and disease.
• Aberrant enhancers can influence cancer risk and oncogene activation, but their mechanisms in cancer are often unclear.
• This study investigates a specific enhancer's role in melanoma.

Purpose of the Study:

• To identify and characterize a novel enhancer involved in melanoma progression.
• To elucidate the molecular mechanism by which this enhancer regulates target genes.
• To explore the therapeutic potential of targeting this enhancer in melanoma.

Main Methods:

• Multi-omics data analysis to identify the enhancer (enh17).
• CRISPR/Cas9 gene editing to delete enh17 in melanoma cells.
• RNA-seq, ChIP-seq, Hi-C, and luciferase reporter assays to identify target genes and transcription factors.
• In vitro and in vivo functional experiments to validate findings.

Main Results:

• An aberrantly activated enhancer, enh17, was identified in melanoma.
• Deletion of enh17 significantly inhibited melanoma cell proliferation, migration, and tumor growth.
• ETV4 was identified as a direct target gene regulated by enh17, with STAT3 as the binding transcription factor.

Conclusions:

• Enhancer enh17 plays a crucial oncogenic role in melanoma progression.
• The study fully elucidated the transcriptional regulatory mechanism of enh17, involving STAT3 and ETV4.
• Targeting enh17 presents a promising therapeutic strategy for melanoma prevention and treatment.